7th IBSE Colloquium
The Seventh Colloquium of the IBSE will be held on 9th February 2021. Dr. Manimozhiyan Arumugam, Group Leader and Associate Professor at the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen has kindly agreed to be our guest speaker. Register here.
Biography of the speaker : Dr. Manimozhiyan Arumugam leads the “Microbiome Systems Biology” research group that investigates how health and diseases are influenced by our gut microbiome; how the gut microbiome interacts with the host and environmental factors; and how we can therapeutically modulate the gut microbiome to improve health. His group takes interdisciplinary approaches combining multi-omics microbiome data to study host-microbial cross-talk. The group also investigates therapeutic approaches to modulate the gut microbiome towards improving human health. Dr. Arumugam has been studying the human microbiome for over 14 years. He is a principal investigator in several studies investigating the role of gut microbiome in multiple sclerosis (Lundbeck Foundation), obesity (Novo Nordisk Foundation – 2 grants), liver disease (European Union Horizon 2020 – 2 grants), ageing (Danish Independent Research Council) and antimicrobial peptides (Danish Independent Research Council – 2 grants). He currently leads Work Packages for microbiome multi-omics data integration in two large EU Horizon 2020 consortia (GALAXY and MICROB-PREDICT) studying liver diseases. Dr. Arumugam has published 53 research articles, 7 of them in Nature (2 as shared first author), 1 in Science and 1 in Cell. He has an h-index of 32 with >19,000 total citations (ISI Web of Science). He was listed among the Highly Cited Researchers of 2018, 2019 and 2020 by Clarivate Analytics.
Biography of the speaker : Dr. Manimozhiyan Arumugam leads the “Microbiome Systems Biology” research group that investigates how health and diseases are influenced by our gut microbiome; how the gut microbiome interacts with the host and environmental factors; and how we can therapeutically modulate the gut microbiome to improve health. His group takes interdisciplinary approaches combining multi-omics microbiome data to study host-microbial cross-talk. The group also investigates therapeutic approaches to modulate the gut microbiome towards improving human health. Dr. Arumugam has been studying the human microbiome for over 14 years. He is a principal investigator in several studies investigating the role of gut microbiome in multiple sclerosis (Lundbeck Foundation), obesity (Novo Nordisk Foundation – 2 grants), liver disease (European Union Horizon 2020 – 2 grants), ageing (Danish Independent Research Council) and antimicrobial peptides (Danish Independent Research Council – 2 grants). He currently leads Work Packages for microbiome multi-omics data integration in two large EU Horizon 2020 consortia (GALAXY and MICROB-PREDICT) studying liver diseases. Dr. Arumugam has published 53 research articles, 7 of them in Nature (2 as shared first author), 1 in Science and 1 in Cell. He has an h-index of 32 with >19,000 total citations (ISI Web of Science). He was listed among the Highly Cited Researchers of 2018, 2019 and 2020 by Clarivate Analytics.